JPS63283596A - Determination of free fatty acid and determinating reagent composition used therein - Google Patents
Determination of free fatty acid and determinating reagent composition used thereinInfo
- Publication number
- JPS63283596A JPS63283596A JP11815887A JP11815887A JPS63283596A JP S63283596 A JPS63283596 A JP S63283596A JP 11815887 A JP11815887 A JP 11815887A JP 11815887 A JP11815887 A JP 11815887A JP S63283596 A JPS63283596 A JP S63283596A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- free fatty
- coenzyme
- reagent
- acyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 52
- 235000021588 free fatty acids Nutrition 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 20
- 239000000194 fatty acid Substances 0.000 claims abstract description 20
- 229930195729 fatty acid Natural products 0.000 claims abstract description 20
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 238000004737 colorimetric analysis Methods 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 4
- 230000003647 oxidation Effects 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 34
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 10
- 239000005516 coenzyme A Substances 0.000 claims description 9
- 229940093530 coenzyme a Drugs 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- -1 acyl coenzyme A Chemical compound 0.000 claims description 5
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 5
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 5
- IWPOSDLLFZKGOW-AATRIKPKSA-N trans-beta-octenoic acid Chemical compound CCCC\C=C\CC(O)=O IWPOSDLLFZKGOW-AATRIKPKSA-N 0.000 claims description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 3
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 claims description 3
- 108020001558 Acyl-CoA oxidase Proteins 0.000 claims description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- JYZJYKOZGGEXSX-UHFFFAOYSA-N 2-hydroxymyristic acid Chemical compound CCCCCCCCCCCCC(O)C(O)=O JYZJYKOZGGEXSX-UHFFFAOYSA-N 0.000 claims 4
- ADLXTJMPCFOTOO-BQYQJAHWSA-N (E)-non-2-enoic acid Chemical compound CCCCCC\C=C\C(O)=O ADLXTJMPCFOTOO-BQYQJAHWSA-N 0.000 claims 2
- JGHSBPIZNUXPLA-UHFFFAOYSA-N 2-hydroxyhexadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)C(O)=O JGHSBPIZNUXPLA-UHFFFAOYSA-N 0.000 claims 2
- NIONDZDPPYHYKY-SNAWJCMRSA-N (2E)-hexenoic acid Chemical compound CCC\C=C\C(O)=O NIONDZDPPYHYKY-SNAWJCMRSA-N 0.000 claims 1
- CWMPPVPFLSZGCY-VOTSOKGWSA-N (2E)-oct-2-enoic acid Chemical compound CCCCC\C=C\C(O)=O CWMPPVPFLSZGCY-VOTSOKGWSA-N 0.000 claims 1
- PAWGRNGPMLVJQH-UHFFFAOYSA-N (E)-2-Dodecenoic acid Natural products CCCCCCCCCC=CC(O)=O PAWGRNGPMLVJQH-UHFFFAOYSA-N 0.000 claims 1
- ADLXTJMPCFOTOO-UHFFFAOYSA-N (E)-2-Nonenoic acid Natural products CCCCCCC=CC(O)=O ADLXTJMPCFOTOO-UHFFFAOYSA-N 0.000 claims 1
- 239000001602 (E)-hex-3-enoic acid Substances 0.000 claims 1
- CBWALJHXHCJYTE-OAHLLOKOSA-N (R)-3-hydroxypalmitic acid Chemical compound CCCCCCCCCCCCC[C@@H](O)CC(O)=O CBWALJHXHCJYTE-OAHLLOKOSA-N 0.000 claims 1
- ATRNZOYKSNPPBF-CYBMUJFWSA-N (R)-3-hydroxytetradecanoic acid Chemical compound CCCCCCCCCCC[C@@H](O)CC(O)=O ATRNZOYKSNPPBF-CYBMUJFWSA-N 0.000 claims 1
- GQVYBECSNBLQJV-QXMHVHEDSA-N (z)-tridec-2-enoic acid Chemical compound CCCCCCCCCC\C=C/C(O)=O GQVYBECSNBLQJV-QXMHVHEDSA-N 0.000 claims 1
- CWMPPVPFLSZGCY-UHFFFAOYSA-N 2-Octenoic Acid Natural products CCCCCC=CC(O)=O CWMPPVPFLSZGCY-UHFFFAOYSA-N 0.000 claims 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 claims 1
- CPVUNKGURQKKKX-UHFFFAOYSA-N 3-Decenoic acid Natural products CCCCCCC=CCC(O)=O CPVUNKGURQKKKX-UHFFFAOYSA-N 0.000 claims 1
- POMQYTSPMKEQNB-UHFFFAOYSA-N 3-hydroxyoctadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)CC(O)=O POMQYTSPMKEQNB-UHFFFAOYSA-N 0.000 claims 1
- OQDNPLAISLNBNS-CMDGGOBGSA-N 3E-Undecenoic acid Chemical compound CCCCCCC\C=C\CC(O)=O OQDNPLAISLNBNS-CMDGGOBGSA-N 0.000 claims 1
- XXHDAWYDNSXJQM-UHFFFAOYSA-N Chloride-3-Hexenoic acid Natural products CCC=CCC(O)=O XXHDAWYDNSXJQM-UHFFFAOYSA-N 0.000 claims 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 claims 1
- ATRNZOYKSNPPBF-UHFFFAOYSA-N D-beta-hydroxymyristic acid Natural products CCCCCCCCCCCC(O)CC(O)=O ATRNZOYKSNPPBF-UHFFFAOYSA-N 0.000 claims 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 claims 1
- NIONDZDPPYHYKY-UHFFFAOYSA-N Z-hexenoic acid Natural products CCCC=CC(O)=O NIONDZDPPYHYKY-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- BCYXFRMDZWKZSF-SNAWJCMRSA-N beta-heptenoic acid Chemical compound CCC\C=C\CC(O)=O BCYXFRMDZWKZSF-SNAWJCMRSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- CPHCIYGRSFZNRD-UHFFFAOYSA-N n-methyl-1-(4,5,6,7-tetrahydro-1h-indazol-3-yl)methanamine Chemical compound C1CCCC2=C1NN=C2CNC CPHCIYGRSFZNRD-UHFFFAOYSA-N 0.000 claims 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 claims 1
- PAWGRNGPMLVJQH-ZHACJKMWSA-N trans-2-dodecenoic acid Chemical compound CCCCCCCCC\C=C\C(O)=O PAWGRNGPMLVJQH-ZHACJKMWSA-N 0.000 claims 1
- CPVUNKGURQKKKX-BQYQJAHWSA-N trans-dec-3-enoic acid Chemical compound CCCCCC\C=C\CC(O)=O CPVUNKGURQKKKX-BQYQJAHWSA-N 0.000 claims 1
- XXHDAWYDNSXJQM-ONEGZZNKSA-N trans-hex-3-enoic acid Chemical compound CC\C=C\CC(O)=O XXHDAWYDNSXJQM-ONEGZZNKSA-N 0.000 claims 1
- IGBBVTAVILYDIO-MDZDMXLPSA-N trans-undec-2-enoic acid Chemical compound CCCCCCCC\C=C\C(O)=O IGBBVTAVILYDIO-MDZDMXLPSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 238000007689 inspection Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 23
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 23
- 102100027441 Nucleobindin-2 Human genes 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 14
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 8
- 238000004445 quantitative analysis Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940005657 pyrophosphoric acid Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は遊離脂肪酸の定量方法、さらに詳しくは特に臨
床検査における血中遊離脂肪酸の定量に適した遊離脂肪
酸の定量方法及びそれに用いる遊離脂肪酸の定量用試薬
組成物に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a method for quantifying free fatty acids, and more specifically, a method for quantifying free fatty acids suitable for quantifying free fatty acids in blood in clinical tests, and a method for quantifying free fatty acids used therein. This invention relates to a quantitative reagent composition.
血液中の遊離脂肪酸(以下NEFAと略す)の定量は、
生体内の脂質代謝に基づくエネルギー状態を反映するこ
とから、臨床的に有意義なものであるとされている。Quantification of free fatty acids (hereinafter abbreviated as NEFA) in blood is as follows:
It is said to be clinically significant because it reflects the energy status based on in vivo lipid metabolism.
NEFAの定量法については、ドールの報告した滴定法
[V、P、Dole、ジャーナル オブクリニ力 イン
ベステイゲーション(J、 Cl1n。Regarding the quantitative determination of NEFA, the titration method reported by Dole [V, P, Dole, Journal of Observatory Investigations (J, Cl1n.
Invest、、 ) 35.150. 1!358年
]以来数多くの定量法が報告されている。たとえば、N
EFAにコバルト [ノバク、エム、; ジャーナル
オブ リピッド リサーチ(Novak、M、; J、
Lipid、Res、、) 6 4311985年]
あるいは銅[ダンコンブ ダブリュ ジー、クリニカ
キミカ アクタ(Dun、combe、W、G−、Cl
1n、 Chin、 Acta ) 9122、 IH
4年1を作用させ、NEFAのコバルト塩あるいは銅塩
として比色定量する方法、またNEFAに、アデノシン
3リン酸(以下ATPと略す)及びコエンザイムA(以
下CoAと略す)存在下アシルコエンザイムA合10&
M素(以下AC5と略す)を作用させ、下記反応人工に
より生成するアシルコエンザイムA lt下アシルCo
Aと略す)やアデノシン1リン酸(以下AMPと略す)
あるいは消費されるC。Invest, ) 35.150. 1!358], many quantitative methods have been reported since then. For example, N
Cobalt in EFA [Novak, M.; Journal
of Lipid Research (Novak, M.; J.
Lipid, Res, ) 6 4311985]
Or copper [Dancombe W, Clinica]
Kimika Acta (Dun, combine, W, G-, Cl
1n, Chin, Acta) 9122, IH
A method of colorimetric determination as a cobalt salt or copper salt of NEFA by reacting NEFA with acyl-coenzyme A in the presence of adenosine triphosphate (hereinafter abbreviated as ATP) and coenzyme A (hereinafter abbreviated as CoA). 10&
Acyl coenzyme A lt lower acyl Co produced by reacting with M element (hereinafter abbreviated as AC5) and producing the following reaction.
A) and adenosine monophosphate (hereinafter abbreviated as AMP)
Or consumed C.
Aを測定する方法−いわゆる酵素法−等が報告されてい
る。A method for measuring A - the so-called enzymatic method - etc. have been reported.
反応式I:
NEFA+ATP+CoA
CS
アシルCoA+AMP+ピロリ
ン酸 (I)
これら定量法のうちコバルトや銅を用いる比色法は、操
作が繁雑なうえ測定精度に劣るため、AC3を利用した
1記反応式Iに基づく定量法が一般化した。Reaction formula I: NEFA + ATP + CoA CS Acyl CoA + AMP + pyrophosphoric acid (I) Among these quantitative methods, the colorimetric method using cobalt or copper is complicated to operate and has poor measurement accuracy, so it is based on reaction formula I using AC3. Quantitative methods became popular.
なかでも反応式Iで生成してくるアシルC。Among them, acyl C produced in reaction formula I.
AをアシルコエンザイムA酸化酵素(以下ACODと略
す)を利用して、下記反応式Hにしたがって酸化する方
法は、測定精度に問題のあるAMPを測定する方法や、
NEFAの定量範囲が限定されてしまうCoA消費量を
測定する方法に比べて操作性、精度、感度等の点で優れ
ていることから現在繁用されている方法である。The method of oxidizing A using acyl coenzyme A oxidase (hereinafter abbreviated as ACOD) according to the following reaction formula H is a method for measuring AMP that has a problem with measurement accuracy,
This method is currently frequently used because it is superior in terms of operability, accuracy, sensitivity, etc. compared to the method of measuring CoA consumption, which has a limited quantitative range for NEFA.
反応式■:
ACOD
アシルCoA+02
2.3−1ランスエノイルコンザエイムA+過酸化水素
(■)ところで、ACODによるア
シルCoAの酸化反応は、試薬として反応系に添加した
CoAの還元作用のため阻害を受ける。したがってAC
ODを用いる測定系を実用化するためには、N−エチル
マレイミド(以下NEMと略す)等、SH試薬の添加に
よって反応式Iにおける未反応のCoAの影響を抑える
必要があった(特公昭57−33955公報)。Reaction formula ■: ACOD acyl-CoA + 02 2.3-1 lansenoylconzaeim A + hydrogen peroxide (■) By the way, the oxidation reaction of acyl-CoA by ACOD is inhibited due to the reducing effect of CoA added to the reaction system as a reagent. receive. Therefore AC
In order to put a measurement system using OD into practical use, it was necessary to suppress the influence of unreacted CoA in Reaction Formula I by adding an SH reagent such as N-ethylmaleimide (hereinafter abbreviated as NEM) (Japanese Patent Publication No. 57 -33955 publication).
しかしながら、ACODは活性中心にSH基を有する酵
素であるため、SH試薬と長時間共存させておくと構造
的破壊を起こし、試薬自体の安定性低下につながる。However, since ACOD is an enzyme having an SH group in its active center, if it is allowed to coexist with an SH reagent for a long time, it will cause structural destruction, leading to a decrease in the stability of the reagent itself.
本発明は、AC3及びACODを利用するNEFAの定
量法において、従来の方法の操作性、精度、感度等を損
うことなく試薬の安定性をも高め得るNEFAの定量方
法及びそのための試薬組成物を提供することを目的とし
ている。The present invention provides a method for quantifying NEFA using AC3 and ACOD, which can improve the stability of the reagent without impairing the operability, accuracy, sensitivity, etc. of conventional methods, and a reagent composition therefor. is intended to provide.
本発明は、検体中の遊離脂肪酸にATPとCoAの存在
下AC3を作用させ、生成するアシルCoAに下記一般
式Iで示される脂肪酸又はその水溶性の塩の存在下でA
CODを作用させ、アシルCoAを酸化して生じる変化
を測定することを特徴とするNEFAの定量方法及び少
なくともATP、CoA及びAC3を含む第1試薬と少
なくとも下記一般式Iで示される脂肪酸又はその水溶性
の塩及びACODを含む第2試薬とから構成されるNE
FA定量用試薬組成物に関するものである。In the present invention, free fatty acids in a sample are treated with AC3 in the presence of ATP and CoA, and the resulting acyl-CoA is treated with A
A method for quantifying NEFA characterized by measuring changes caused by oxidizing acyl-CoA by applying COD, and a first reagent containing at least ATP, CoA and AC3, and at least a fatty acid represented by the following general formula I or an aqueous solution thereof and a second reagent containing an ACOD salt.
This invention relates to a reagent composition for quantifying FA.
一般式I:
R−A −(CH2)n−COOH
(式中、Rは炭素数1〜20の脂肪族基を表し、nはO
又は1〜2の整数を表し、
Aは−CH=CH−又は
Z
Y及びZは水素原子、水酸基又は低級アルキル基を表す
、ただしYとZは同時に水素原子を表さない、)
本発明における上記一般式!で示される脂肪酸は、下記
反応式mで示される反応に従って、試薬として添加した
CoA及びATPの存在下AC3の作用を受け、ACO
Dの基質となり得ない物質を生成する。General formula I: R-A-(CH2)n-COOH (wherein, R represents an aliphatic group having 1 to 20 carbon atoms, and n is O
or represents an integer of 1 to 2, A is -CH=CH- or Z Y and Z represent a hydrogen atom, a hydroxyl group or a lower alkyl group, provided that Y and Z do not represent a hydrogen atom at the same time) In the present invention General formula above! The fatty acid represented by is subjected to the action of AC3 in the presence of CoA and ATP added as reagents according to the reaction represented by the following reaction formula m, and is converted to
Produces a substance that cannot be a substrate for D.
反応式■:
FA+COA+ATP
C3
一−−−→F A −Co A + A M P +ピ
ロリン酸
(m)
(式中、FAは上記一般式lで示される脂肪酸を示し、
FA−CoAはACOD(7)基質となり得ない物質を
示す)
上記一般式!で示される脂肪酸と、この脂肪酸をもとに
反応式■に従って生成されるACODの基質となり得な
い物質との関係を、具体的な物質として列挙すれば、例
えば第1表に示す如きものが挙げられる。Reaction formula ■: FA + COA + ATP C3 - - - → FA -Co A + A M P + pyrophosphoric acid (m) (wherein, FA represents the fatty acid represented by the above general formula 1,
FA-CoA indicates a substance that cannot be a substrate for ACOD (7)) The above general formula! If we enumerate the relationship between the fatty acid represented by and substances that cannot be substrates for ACOD, which are produced based on this fatty acid according to reaction formula ①, for example, those shown in Table 1 are listed as specific substances. It will be done.
第1表
上記一般式Iで示される脂肪酸の使用敬は、試料中の予
想されるNEFAの儂度並びに反応液中に存在するCo
Aの絶対量にもよるが、CoAに対するモル比が1以上
、好ましくは5〜50程度とするとよい。Table 1 The use of the fatty acid represented by the above general formula I is determined based on the expected degree of NEFA in the sample and the amount of Co present in the reaction solution.
Although it depends on the absolute amount of A, the molar ratio to CoA is preferably 1 or more, preferably about 5 to 50.
また、ACODはpH8,0〜8.5の範囲内で作用さ
せるとよい。Furthermore, ACOD is preferably allowed to act within the range of pH 8.0 to 8.5.
本発明によるNEFAの定量方法において、ACODの
作用により生じる変化を検出する方法としては、次のよ
うなものが挙げられる。In the method for quantifying NEFA according to the present invention, methods for detecting changes caused by the action of ACOD include the following.
■ ACODの作用により生成する過酸化水素を公知の
方法で測定する。(2) Hydrogen peroxide produced by the action of ACOD is measured by a known method.
■ ACODの作用により消費される酵素を公知の方法
で測定する。(2) Measure the enzyme consumed by the action of ACOD using a known method.
なかでも現在臨床検査の分野で繁用されている過酸化水
素の比色法による測定方法は、これまでのNEFAの定
量法にも利用されていたものなので、特別な装置や熟練
を必要としないので、好ましい方法である。Among them, the colorimetric method for measuring hydrogen peroxide, which is currently frequently used in the field of clinical testing, is the same method used in the NEFA quantitative method, so it does not require special equipment or skill. Therefore, this is the preferred method.
本発明によるNEFAの定量用組成物における上記一般
式1の脂肪酸以外の物質は、従来の酵素法に基づく定量
用組成物に使用されるものと同様のものを用いることが
できる。すなわち、第1試薬には、リン酸、ホウ酸、ク
エン酸等適当な緩衝剤や、必要に応じて防腐剤や、公知
の安定剤等を加えることが可能である。同様に第2試薬
についても、緩衝剤、防腐剤及び安定剤等を加えること
ができる。更に第1試薬あるいは第2試薬には、ACO
Dの作用により生じる変化を検出し得る試薬系を共存さ
せることも可能である。Substances other than the fatty acid of general formula 1 in the composition for quantitative determination of NEFA according to the present invention can be the same as those used in compositions for quantitative determination based on conventional enzyme methods. That is, an appropriate buffer such as phosphoric acid, boric acid, citric acid, etc., and if necessary, a preservative, a known stabilizer, etc. can be added to the first reagent. Similarly, for the second reagent, buffers, preservatives, stabilizers, etc. can be added. Furthermore, the first reagent or the second reagent contains ACO
It is also possible to coexist a reagent system that can detect changes caused by the action of D.
このような試薬系として広く知られているものとしては
、ACODの作用で生成してくる過酸化水素の測定試薬
系が挙げられる。具体的には、ペルオキシダーゼ(以下
PODと略す)やカタラーゼを使用するものが挙げられ
る。これらは、PODやカタラーゼの作用により、例え
ば下記反応式〇〜■に基づいて色素を生成させ、これを
比色定量するものである。A widely known example of such a reagent system is a reagent system for measuring hydrogen peroxide produced by the action of ACOD. Specifically, examples include those using peroxidase (hereinafter abbreviated as POD) and catalase. In these methods, a pigment is produced by the action of POD or catalase, based on, for example, the following reaction formulas 〇 to 〇, and this is colorimetrically quantified.
■ 過酸化水素+4−7ミノアンチピリン+アニリン化
合物あるいはフェノール化合物OD
キノン色素子H20
t7 過酸化水素子ベンチジン化合物OD
キノン色素子H20
本発明による試薬組成物は、溶解状態のみならず、凍結
乾燥等の方法により乾燥状態で提供することも可能であ
る。■ Hydrogen peroxide + 4-7 minoantipyrine + aniline compound or phenol compound OD Quinone dye H20 t7 Hydrogen peroxide benzidine compound OD Quinone dye H20 The reagent composition according to the present invention can be used not only in a dissolved state but also in a lyophilized state It is also possible to provide it in a dry state depending on the method.
本発明によるNEFAの定量方法及び試薬組成物におけ
る前記一般式1で示される脂肪酸は、ACODの作用に
よって進行する前記反応式■で示される反応をCoAが
妨害するのを抑える作用を有する。すなわち、前記反応
式Iにおいて、NEFAとの反応にあずからなかったC
oA及びATPを、前記一般式1で表される脂肪酸とA
C3の存在下で反応させてACODの作用しない物質と
し、反応の系外に出してしまうのである。The fatty acid represented by the general formula 1 in the method and reagent composition for quantifying NEFA according to the present invention has the effect of suppressing CoA from interfering with the reaction represented by the reaction formula (2) that proceeds due to the action of ACOD. That is, in the reaction formula I, C that did not participate in the reaction with NEFA
oA and ATP, a fatty acid represented by the general formula 1 and A
By reacting in the presence of C3, it becomes a substance that does not act on ACOD, and it is taken out of the reaction system.
以下、本発明を実施例により説明する。 The present invention will be explained below using examples.
実施例1
次に示す第1試薬及び第2試薬を用いてNEFAの定量
を行った。Example 1 NEFA was quantified using the following first and second reagents.
0第1試薬
・リン酸緩衝液(PH8,8) 50■阿・ A
TP 2■N・塩
化マグネシウム・
6水和物 5mM
・4−7ミノアンチピリン 2mM
・CoAリチウム塩 0.2鵬に・AC3(
比活性2U/鵬g
タンパク)0.3鵬g/s文
・ ) IJ ト 7X −1000,1g/d
JlO第2試薬
・リン酸緩衝液(pH8,8) 50簡に・N−
エチル−N−(0−
メチルスルホンアミドエチル)
m−)ルイジン 2論圓
・前記一般式Iで示される
脂肪酸(第2表参照) 2■貢
・POD (比活性100U/mg
タンパク) 0.04簡g/■交・
ACOD (比活性20U/sg
タンパク) 0.25簡g/■見・
)!JトンX−1000,05g/dll尚試料として
は、オレイン酸ナトリウム30.45鵬8 を )
リ ) 7X −1005g/di溶液10m1k:
溶解後、同溶液で全量10〇−文としたものを用いた。01st reagent/phosphate buffer (PH8,8) 50■A・A
TP 2■N・Magnesium chloride・Hexahydrate 5mM・4-7 minoantipyrine 2mM・CoA lithium salt 0.2P・AC3(
Specific activity 2U/Peng Protein) 0.3Peng/s Bun・) IJ To 7X -1000, 1g/d
JlO second reagent/phosphate buffer (pH 8,8) 50 ml/N-
Ethyl-N-(0-methylsulfonamidoethyl) m-)luidine 2. Fatty acid represented by the above general formula I (see Table 2) 2. Tribute. POD (specific activity 100 U/mg protein) 0.04 Simple g/■ 交・
ACOD (specific activity 20U/sg protein) 0.25g/■mi・
)! Jton
) 7X -1005g/di solution 10ml 1k:
After dissolving, the total volume was made up to 100% using the same solution.
測定操作は次のとおりである。The measurement operation is as follows.
■ 試料50ル交と第1試薬is文を混合し、37℃に
て5分間反応させる。■ Mix 50 samples and the first reagent IS, and react at 37°C for 5 minutes.
■ 更に第2試薬2層見を加え、37℃にて5分間反応
させた後555nmにおける吸光度を測定する。(2) Add two more layers of the second reagent and react at 37°C for 5 minutes, then measure the absorbance at 555 nm.
従来法として、第2試薬中の脂肪酸にかえてNEMlm
Mを加えたものを用いて同様の操作に従い定量を行って
、得られた結果を比較した。As a conventional method, NEMlm was used instead of the fatty acid in the second reagent.
Quantification was performed in the same manner using a sample containing M, and the obtained results were compared.
結果を第2表に示す。The results are shown in Table 2.
第 2 表
前記一般式Iで示される脂肪酸による
CoAの影響の抑制効果
尚NEMを利用した場合の光学的密度は0.26程度で
あった。Table 2 Effect of suppressing the influence of CoA by the fatty acid represented by the general formula I. The optical density when NEM was used was about 0.26.
実施例2
前記一般式■で示される脂肪酸として3−オクテン酸を
利用した本発明によるNE FA定量法と、NEMを利
用した従来法とで得られる結果の相間々係を調査した。Example 2 The relationship between the results obtained by the NEFA quantitative method according to the present invention using 3-octenoic acid as the fatty acid represented by the general formula (1) and the conventional method using NEM was investigated.
本発明によるNEFAの定量法は実施例1と同様の操作
に従い、従来法はNEMを含む市販のNEFA定量用試
薬を利用し、操作は取扱い説明書の記載に従って行った
。The method for quantifying NEFA according to the present invention followed the same procedure as in Example 1, and the conventional method used a commercially available reagent for quantifying NEFA containing NEM, and the procedure was performed according to the instruction manual.
尚各々の定量法について、試料の定量とは別に501L
jLの精製水を用いて同様の操作を行って試薬ブランク
の光学的密度を求め、下記計算式を用いてNEFA値(
JLE q/jL)を算出した。試料としては、ヒト血
清15検体を、標準試料としてはオレイン酸のtoo。In addition, for each quantitative method, 501L is required separately from the sample determination.
The same operation was performed using jL of purified water to determine the optical density of the reagent blank, and the NEFA value (
JLE q/jL) was calculated. The samples were 15 human serum samples, and the standard sample was too much oleic acid.
JLE q/ l (30,45mg/dll、実施例
1で調製したものと同一)溶液を用いた。A JLE q/l (30.45 mg/dll, same as that prepared in Example 1) solution was used.
計算式
本発明によるNEFAの定量法と従来法との間には、第
3表に示すとおり良好な相関々係が見られた。Calculation formula As shown in Table 3, there was a good correlation between the method for quantifying NEFA according to the present invention and the conventional method.
第 3 表
ちなみに本発明によるNEFAの定量法における検量線
は、第1図に示すとおり、原点Oを通る直線性の良いも
のであった。Table 3 Incidentally, the calibration curve in the method for quantifying NEFA according to the present invention had good linearity passing through the origin O, as shown in FIG.
実施例3
第2試薬に3−オクテン酸(本発明)又はNEM(従来
法)を加えた場合のACODの安定性を調査した。Example 3 The stability of ACOD was investigated when 3-octenoic acid (invention) or NEM (conventional method) was added to the second reagent.
3−オクテン酸 2膳に又はNEM 1層踵を含む第
2試薬を、溶解状態で次の2つの条件のもとに放置し、
試薬の反応性を比較した。A second reagent containing two portions of 3-octenoic acid or one layer of NEM is left in a dissolved state under the following two conditions;
The reactivity of the reagents was compared.
0条件l:25℃で4日間放置し、実際に血清を用いて
定量操作を行い、第2試薬のタイムコースを観察した。0 condition 1: The sample was left at 25° C. for 4 days, a quantitative operation was actually performed using serum, and the time course of the second reagent was observed.
結果を第2図及び第3図に示す。The results are shown in FIGS. 2 and 3.
O条件2:2〜lθ℃で24日間放置し、実際に血清を
用いて定量操作を行い、第2試薬のタイムコースを観察
した。結果を第4図及び第5図に示す。O condition 2: The sample was left for 24 days at 2-1θ°C, and a quantitative operation was actually performed using serum to observe the time course of the second reagent. The results are shown in FIGS. 4 and 5.
条件l及び2において、第2試薬中の過酸化水J測定用
試薬系の安定性を確認するために標準試料にかえて、過
酸化水素溶液を加えて発色状態を観察したが、各試薬間
での差はほとんどみられず、第2図ないし第5図におけ
る試薬間のNEM添加に起因する反応性のちがいは、A
CODの活性低下によるものと考えられた。In conditions 1 and 2, in order to confirm the stability of the reagent system for measuring peroxide water J in the second reagent, a hydrogen peroxide solution was added instead of the standard sample and the state of color development was observed. There was almost no difference in reactivity between the reagents in Figures 2 to 5, which was caused by the addition of NEM.
This was thought to be due to a decrease in COD activity.
又、条件lにおいて、ACOD比活性をオースミらによ
るバイオケミカル アンドバイオ フィジカル リサー
チ コ ミ ユニケージ、 y (O8UMI et
al、 Biochem、 Biophys、 Res
、 Goms、 83.2.479−485(1978
))記載の方法に従って測定し、保存中の活性変化を観
察した。その結果、試薬調製直後のACOD活性を 1
00とすると、4日後のACOD活性は、NEMを使っ
た従来法では18.8%、3−オクテン酸を使った本発
明法では80.1%という値が得られ、NEMの添加を
避けることでACOD活性の低下が著るしく抑制される
ことが明らかであった。In addition, under condition 1, the specific activity of ACOD was determined by O8UMI et al.
al, Biochem, Biophys, Res
, Goms, 83.2.479-485 (1978
)) Measurements were made according to the method described, and changes in activity during storage were observed. As a result, the ACOD activity immediately after reagent preparation was 1
00, the ACOD activity after 4 days was 18.8% with the conventional method using NEM and 80.1% with the present method using 3-octenoic acid, so it is important to avoid adding NEM. It was clear that the decrease in ACOD activity was significantly suppressed.
本発明によれば、ACODの保存安定性に悪影響を及ぼ
すと考えられるNEM等のSR試薬を用いないNEFA
の定量方法及びそのための試薬組成物を提供し得る。試
薬成分の安定性の向上は、溶液状態で供給されることの
多い自動分析装置用の試薬において特に多大な効果を奏
するものと考えられる。According to the present invention, NEFA does not use an SR reagent such as NEM, which is considered to have an adverse effect on the storage stability of ACOD.
and a reagent composition for the same. Improving the stability of reagent components is considered to have a particularly great effect on reagents for automatic analyzers, which are often supplied in the form of solutions.
第1図は本発明によるNEFAの定量法における検量線
を示すグラフ、
第2図及び第4図は従来法による、また第3図及び第5
図は本発明法によるACODの安定性を示すグラフであ
る。FIG. 1 is a graph showing the calibration curve in the NEFA quantitative method according to the present invention, FIGS. 2 and 4 are graphs showing the calibration curve according to the conventional method, and FIGS.
The figure is a graph showing the stability of ACOD according to the method of the present invention.
Claims (7)
ンザイムAの存在下アシルコエンザイムA合成酵素を作
用させ、生成するアシルコエンザイムAに、下記一般式
I で示される脂肪酸又はその水溶性の塩の存在下でア
シルコエンザイムA酸化酵素を作用させ、アシルコエン
ザイムAの酸化によって生じる変化を測定することを特
徴とする遊離脂肪酸の定量方法。 一般式 I : R−A−(CH_2)_n−COOH (式中、Rは炭素数1〜20の脂肪族基を表し、nは0
又は1〜2の整数を表し、 Aは−CH=CH−又は ▲数式、化学式、表等があります▼を表し、 Y及びZは水素原子、水酸基又は低級アル キル基を表す、ただしYとZは同時に水素 原子を表さない。)(1) Acyl-coenzyme A synthetase is allowed to act on free fatty acids in a sample in the presence of adenosine triphosphate and coenzyme A, and the resulting acyl-coenzyme A is expressed by the following general formula:
1. A method for quantifying free fatty acids, which comprises allowing acyl-coenzyme A oxidase to act in the presence of a fatty acid represented by I or a water-soluble salt thereof, and measuring changes caused by oxidation of acyl-coenzyme A. General formula I: R-A-(CH_2)_n-COOH (wherein, R represents an aliphatic group having 1 to 20 carbon atoms, and n is 0
or represents an integer from 1 to 2, A represents -CH=CH- or ▲There are mathematical formulas, chemical formulas, tables, etc.▼, Y and Z represent hydrogen atoms, hydroxyl groups, or lower alkyl groups, provided that Y and Z are At the same time, it does not represent a hydrogen atom. )
、3−ヘキセン酸、2−ヘプテン酸、3−ヘプテン酸、
2−オクテン酸、3−オクテン酸、2−ノネン酸、3−
ノネン酸、2−デセン酸、3−デセン酸、2−ウンデセ
ン酸、3−ウンデセン酸、2−ドデセン酸、2−トリデ
セン酸及び2−ヘキサデセン酸から成る群から選択され
たものであることを特徴とする特許請求の範囲第1項記
載の遊離脂肪酸の定量方法。(2) The fatty acid represented by the general formula I is 2-hexenoic acid, 3-hexenoic acid, 2-heptenoic acid, 3-heptenoic acid,
2-octenoic acid, 3-octenoic acid, 2-nonenoic acid, 3-
selected from the group consisting of nonenoic acid, 2-decenoic acid, 3-decenoic acid, 2-undecenoic acid, 3-undecenoic acid, 2-dodecenoic acid, 2-tridecenoic acid and 2-hexadenoic acid. A method for quantifying free fatty acids according to claim 1.
ミリスチン酸、3−ヒドロキシミリスチン酸、2−ヒド
ロキシパルミチン酸、3−ヒドロキシパルミチン酸、2
−ヒドロキシステアリン酸、3−ヒドロキシステアリン
酸から成る群から選択されたものであることを特徴とす
る特許請求の範囲第1項記載の遊離脂肪酸の定量方法。(3) The fatty acid represented by the general formula I is 2-hydroxymyristic acid, 3-hydroxymyristic acid, 2-hydroxypalmitic acid, 3-hydroxypalmitic acid, 2-hydroxymyristic acid,
2. The method for quantifying free fatty acids according to claim 1, wherein the fatty acid is selected from the group consisting of -hydroxystearic acid and 3-hydroxystearic acid.
素を測定することを特徴とする特許請求の範囲第1項記
載の遊離脂肪酸の定量方 法。(4) The method for quantifying free fatty acids according to claim 1, which comprises measuring hydrogen peroxide produced by oxidizing acyl coenzyme A.
する特許請求の範囲第5項記載の遊離脂肪酸の定量方法
。(5) The method for quantifying free fatty acids according to claim 5, characterized in that hydrogen peroxide is determined by a colorimetric method.
及びアシルコエンザイムA合成酵素を含む第1試薬と、
少なくとも下記一般式 I で示される脂肪酸又はその水
溶性の塩及びアシルコエンザイムA酸化酵素を含む第2
試薬とから構成されることを特徴とする遊離脂肪酸定量
用試薬組成物。 一般式 I : R−A−(CH_2)_n−COOH (式中、Rは炭素数1〜20の脂肪族基を表し、nは0
又は1〜2の整数を表し、 Aは−CH=CH−又は ▲数式、化学式、表等があります▼を表し、 Y及びZは水素原子、水酸基又は低級アル キル基を表す、ただしYとZは同時に水素 原子を表さない。)(6) At least adenosine triphosphate, coenzyme A
and a first reagent comprising acyl-coenzyme A synthase;
A second compound containing at least a fatty acid represented by the following general formula I or a water-soluble salt thereof and an acyl coenzyme A oxidase.
A reagent composition for quantifying free fatty acids, comprising a reagent. General formula I: R-A-(CH_2)_n-COOH (wherein, R represents an aliphatic group having 1 to 20 carbon atoms, and n is 0
or represents an integer from 1 to 2, A represents -CH=CH- or ▲There are mathematical formulas, chemical formulas, tables, etc.▼, Y and Z represent hydrogen atoms, hydroxyl groups, or lower alkyl groups, provided that Y and Z are At the same time, it does not represent a hydrogen atom. )
成物を含むことを特徴とする特許請求の範囲第6項記載
の遊離脂肪酸定量用試薬組成物。(7) The reagent composition for quantifying free fatty acids according to claim 6, wherein the second reagent further contains a reagent composition for hydrogen peroxide colorimetric measurement.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11815887A JPH0630630B2 (en) | 1987-05-15 | 1987-05-15 | Method for quantifying free fatty acid and reagent composition for quantification used therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11815887A JPH0630630B2 (en) | 1987-05-15 | 1987-05-15 | Method for quantifying free fatty acid and reagent composition for quantification used therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63283596A true JPS63283596A (en) | 1988-11-21 |
JPH0630630B2 JPH0630630B2 (en) | 1994-04-27 |
Family
ID=14729536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11815887A Expired - Fee Related JPH0630630B2 (en) | 1987-05-15 | 1987-05-15 | Method for quantifying free fatty acid and reagent composition for quantification used therefor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0630630B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016520655A (en) * | 2013-06-04 | 2016-07-14 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | Protein purification process |
JP2017507149A (en) * | 2014-02-27 | 2017-03-16 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | Antibody purification method |
-
1987
- 1987-05-15 JP JP11815887A patent/JPH0630630B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016520655A (en) * | 2013-06-04 | 2016-07-14 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | Protein purification process |
US10174076B2 (en) | 2013-06-04 | 2019-01-08 | Agency For Science, Technology And Research | Protein purification process |
JP2017507149A (en) * | 2014-02-27 | 2017-03-16 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | Antibody purification method |
US10160784B2 (en) | 2014-02-27 | 2018-12-25 | Agency For Science, Technology And Research | Antibody purification process |
Also Published As
Publication number | Publication date |
---|---|
JPH0630630B2 (en) | 1994-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS61146196A (en) | Method and reagent for improving photometry of h202 | |
US4215197A (en) | Test means and method for creatinine determination | |
JPS6134799B2 (en) | ||
CN107505273A (en) | Serum tolal bile acid assay kit and its application method | |
CN111808921A (en) | Trinder reaction-based detection kit and application thereof | |
JPS6324900A (en) | Stabilized liquid enzyme composition for quantifying glucose, test kit using the same and quantifying method | |
CN101498662A (en) | Reagent kit for monoamine oxidase MAO single-reagent measurement | |
CN111944872A (en) | Reagent combination, reagent or kit for measuring creatinine content | |
EP0140589B1 (en) | Enzymatic determination of d-3-hydroxybutyric acid or acetoacetic acid, and reagents therefor | |
JPH04287695A (en) | Composition for analyzing ethanol | |
US4810642A (en) | Method and test composition for determination of hydrogen peroxide | |
JPS59230161A (en) | Method and reagent for decomposing reducing material | |
KR100312056B1 (en) | Methods and reagents for quantitatively determining ascorbic acid | |
JPS63283596A (en) | Determination of free fatty acid and determinating reagent composition used therein | |
US5266472A (en) | Stabilization of the enzyme urate oxidase in liquid form | |
JP2000316600A (en) | Method for determining free fatty acid and reagent for determining free fatty acid | |
JP2704616B2 (en) | Free fatty acid determination method and reagent composition for free fatty acid determination useful for the determination method | |
US5888828A (en) | Kit for measuring urea nitrogen | |
WO1995006135A1 (en) | Method of determining sodium ion | |
JP2003235600A (en) | Liquid reagent for measuring free fatty acid (nefa) | |
JP4182859B2 (en) | Liquid reagent kit for measuring creatine kinase and stabilization method thereof | |
JP4067147B2 (en) | Method and reagent for measuring creatine phosphokinase activity | |
JP3522307B2 (en) | Liquid reagent composition for measuring inorganic phosphorus | |
JP2515551B2 (en) | Novel method for quantifying hydrogen peroxide | |
CN118006725A (en) | Creatinine detection kit and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |